Literature DB >> 25682896

Low programmed cell death-1 (PD-1) expression in peripheral CD4(+) T cells in Japanese patients with autoimmune type 1 diabetes.

R Fujisawa1, F Haseda1, C Tsutsumi1, Y Hiromine2, S Noso2, Y Kawabata2, S Mitsui1, J Terasaki1, H Ikegami2, A Imagawa1,3, T Hanafusa1.   

Abstract

Programmed cell death-1 (PD-1) is a co-stimulatory molecule that inhibits T cell proliferation. We aimed to clarify PD-1 expression in CD4(+) T cells and the association between PD-1 expression and the 7785C/T polymorphism of PDCD1, with a focus on the two subtypes of type 1 diabetes, type 1A diabetes (T1AD) and fulminant type 1 diabetes (FT1D), in the Japanese population. We examined 22 patients with T1AD, 15 with FT1D, 19 with type 2 diabetes (T2D) and 29 healthy control (HC) subjects. Fluorescence-activated cell sorting (FACS) and real-time PCR were utilized to analyse PD-1 expression quantitatively. Genotyping of 7785C/T in PDCD1 was performed using the TaqMan method in a total of 63 subjects (21 with T1AD, 15 with FT1D and 27 HC). FACS revealed a significant reduction in PD-1 expression in CD4(+) T cells in patients with T1AD (mean: 4.2 vs. 6.0% in FT1D, P=0.0450; vs. 5.8% in T2D, P=0.0098; vs. 6.0% in HC, P=0.0018). PD-1 mRNA expression in CD4(+) T cells was also significantly lower in patients with T1AD than in the HC subjects. Of the 63 subjects, PD-1 expression was significantly lower in individuals with the 7785C/C genotype than in those with the C/T and T/T genotypes (mean: 4.1 vs. 5.9%, P=0.0016). Our results indicate that lower PD-1 expression in CD4(+) T-cells might contribute to the development of T1AD through T cell activation.
© 2015 British Society for Immunology.

Entities:  

Keywords:  PD-1; fulminant type 1 diabetes; type 1A diabetes

Mesh:

Substances:

Year:  2015        PMID: 25682896      PMCID: PMC4449773          DOI: 10.1111/cei.12603

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  37 in total

1.  Diagnosis and classification of diabetes mellitus.

Authors: 
Journal:  Diabetes Care       Date:  2014-01       Impact factor: 19.112

Review 2.  Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners.

Authors:  Toshiaki Hanafusa; Akihisa Imagawa
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2007-01

3.  Pathologic anatomy of the pancreas in juvenile diabetes mellitus.

Authors:  W Gepts
Journal:  Diabetes       Date:  1965-10       Impact factor: 9.461

4.  Low CTLA-4 expression in CD4+ helper T-cells in patients with fulminant type 1 diabetes.

Authors:  Fumitaka Haseda; Akihisa Imagawa; Yuko Murase-Mishiba; Hiroyuki Sano; Suzue Hirano-Kuwata; Hironori Ueda; Jungo Terasaki; Toshiaki Hanafusa
Journal:  Immunol Lett       Date:  2011-05-17       Impact factor: 3.685

5.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359

6.  Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus.

Authors:  Shih-Chang Lin; Jeng-Hsien Yen; Jaw-Ji Tsai; Wen-Chen Tsai; Tsan-Teng Ou; Hong-Wen Liu; Chung-Jen Chen
Journal:  Arthritis Rheum       Date:  2004-03

7.  Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease.

Authors:  Daria Trabattoni; Marina Saresella; Michela Pacei; Ivana Marventano; Laura Mendozzi; Marco Rovaris; Domenico Caputo; Manuela Borelli; Mario Clerici
Journal:  J Immunol       Date:  2009-09-30       Impact factor: 5.422

8.  Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes.

Authors:  C Nielsen; D Hansen; S Husby; B B Jacobsen; S T Lillevang
Journal:  Tissue Antigens       Date:  2003-12

9.  PD-1, but not PD-L1, expressed by islet-reactive CD4+ T cells suppresses infiltration of the pancreas during type 1 diabetes.

Authors:  Kristen E Pauken; Marc K Jenkins; Miyuki Azuma; Brian T Fife
Journal:  Diabetes       Date:  2013-04-04       Impact factor: 9.461

10.  The candidate genes TAF5L, TCF7, PDCD1, IL6 and ICAM1 cannot be excluded from having effects in type 1 diabetes.

Authors:  Jason D Cooper; Deborah J Smyth; Rebecca Bailey; Felicity Payne; Kate Downes; Lisa M Godfrey; Jennifer Masters; Lauren R Zeitels; Adrian Vella; Neil M Walker; John A Todd
Journal:  BMC Med Genet       Date:  2007-11-28       Impact factor: 2.103

View more
  33 in total

1.  Decreased expression of programmed death-1 on CD8+ effector memory T lymphocytes correlates with the pathogenesis of type 1 diabetes.

Authors:  Yimei Shan; Yinghong Kong; Yan Zhou; Jingjing Guo; Qiyun Shi; Sicheng Li; Heming Guo; Yiting Huang; Sisi Ding; Cuiping Liu; Lei Cao; Yun Huang; Chen Fang; Ji Hu
Journal:  Acta Diabetol       Date:  2021-04-23       Impact factor: 4.280

Review 2.  Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature.

Authors:  Laura Hickmott; Hugo De La Peña; Helen Turner; Fathelrahman Ahmed; Andrew Protheroe; Ashley Grossman; Avinash Gupta
Journal:  Target Oncol       Date:  2017-04       Impact factor: 4.493

Review 3.  Patient-Centered Diabetes Care of Cancer Patients.

Authors:  Anupam Kotwal; Yee-Ming M Cheung; Grace Cromwell; Andjela Drincic; Houry Leblebjian; Zoe Quandt; Robert J Rushakoff; Marie E McDonnell
Journal:  Curr Diab Rep       Date:  2021-12-13       Impact factor: 4.810

4.  Hyperosmolar Hyperglycaemic State and Diabetic Ketoacidosis in Nivolumab-Induced Insulin-Dependent Diabetes Mellitus.

Authors:  Ahmed Osman Saleh; Ruba Taha; Shehab Fareed A Mohamed; Mohammed Bashir
Journal:  Eur J Case Rep Intern Med       Date:  2021-08-13

5.  New onset diabetes after nivolumab treatment.

Authors:  Ricardo Capitao; Carlos Bello; Ricardo Fonseca; Catarina Saraiva
Journal:  BMJ Case Rep       Date:  2018-01-29

6.  Atezolizumab-induced type 1 diabetes mellitus in a patient with metastatic renal cell carcinoma.

Authors:  Wedad Rahman; Anna Conley; Kristi D Silver
Journal:  BMJ Case Rep       Date:  2020-07-02

7.  Expression of PD-1 Molecule on Regulatory T Lymphocytes in Patients with Insulin-Dependent Diabetes Mellitus.

Authors:  Valentina Perri; Benedetta Russo; Antonino Crinò; Riccardo Schiaffini; Ezio Giorda; Marco Cappa; Maria Manuela Rosado; Alessandra Fierabracci
Journal:  Int J Mol Sci       Date:  2015-09-18       Impact factor: 5.923

8.  Exploring the induction of preproinsulin-specific Foxp3(+) CD4(+) Treg cells that inhibit CD8(+) T cell-mediated autoimmune diabetes by DNA vaccination.

Authors:  Katja Stifter; Cornelia Schuster; Michael Schlosser; Bernhard Otto Boehm; Reinhold Schirmbeck
Journal:  Sci Rep       Date:  2016-07-11       Impact factor: 4.379

9.  The Expression of Programmed Death-1 on CD4+ and CD8+ T Lymphocytes in Patients with Type 2 Diabetes and Severe Sepsis.

Authors:  Yumei Jia; Yongzhen Zhao; Chunsheng Li; Rui Shao
Journal:  PLoS One       Date:  2016-07-26       Impact factor: 3.240

10.  Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy.

Authors:  Masahide Okamoto; Mitsuhiro Okamoto; Koro Gotoh; Takayuki Masaki; Yoshinori Ozeki; Hisae Ando; Manabu Anai; Asami Sato; Yuichi Yoshida; So Ueda; Tetsuya Kakuma; Hirotaka Shibata
Journal:  J Diabetes Investig       Date:  2016-05-31       Impact factor: 4.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.